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RESEARCH ARTICLE
Relation between Red Cell Distribution Width
and Fibroblast Growth Factor 23 Cleaving in
Patients with Chronic Kidney Disease and
Heart Failure
Fenna van Breda1*, Mireille E. Emans2, Karien van der Putten3, Branko Braam4, Frans
J. van Ittersum1, Rob J. Kraaijenhagen5, Martin H. de Borst6, Marc Vervloet1, Carlo A. J.
M. Gaillard6
1 Department of Nephrology and ICaR-VU, VUMC, Amsterdam, the Netherlands, 2 Department of
Cardiology, Ikazia Hospital, Rotterdam, the Netherlands, 3 Department of Internal Medicine, TerGooi
Hospital, Hilversum, the Netherlands, 4 Department of Medicine, division of Nephrology and Immunology,
University of Alberta, Edmonton, Canada, 5 Department of Clinical Chemistry, Meander Medical Center,




In chronic kidney disease (CKD), both anemia and deregulated phosphate metabolism are
common and predictive of adverse outcome. Previous studies suggest that iron status influ-
ences phosphate metabolism by modulating proteolytic cleavage of FGF23 into C-terminal
fragments. Red cell distribution width (RDW) was recently identified as a strong prognostic
determinant for cardiovascular morbidity and mortality, independently of iron status. We
assessed whether RDW is associated with FGF23 cleaving in CKD patients with heart
failure.
Materials and Methods
The associations between RDW and either intact FGF23 (iFGF23), C-terminal FGF23
(cFGF23, reflecting iFGF23 and C-terminal fragments together) and the iFGF23/cFGF23
ratio were analyzed in 52 patients with CKD (eGFR 34,9 ± 13.9 ml/min/1.73m2) and chronic
heart failure (CHF). Associations between RDW and FGF23 forms were studied by linear
regression analysis adjusted for parameters of renal function, iron metabolism, phosphate
metabolism and inflammation.
Results
Median cFGF23 levels were 197.5 [110–408.5] RU/ml, median iFGF23 levels were 107.3
[65.1–162.2] pg/ml and median FGF23 ratio was 0.80 [0.37–0.86]. Mean RDW was 14.1 ±
1.2%. cFGF23 and RDWwere associated (β = 1.63x10-3, P <0.001), whereas iFGF23 and
RDWwere not (β = -1.38x10-3, P = 0.336). The iFGF23/cFGF23 ratio was inversely
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associated with RDW. The difference between cFGF23 and iFGF23 (cFGF23- iFGF23)
was positively associated with RDW (β = 1.74x10-3, P< 0.001). The association between
cFGF23 and RDW persisted upon multivariable linear regression analysis, adjusted for
parameters of renal function, phosphate metabolism, iron metabolism and inflammation
(β = 0.97x10-3, P = 0.047).
Conclusion
RDW is associated with cFGF23 but not with iFGF23 levels in patients with CKD and CHF.
This suggests a connection between RDW and FGF23 catabolism, independent of iron sta-
tus and inflammation. Future studies are needed to unravel underlying mechanisms and
whether these pertain to the link between RDW and outcome.
Introduction
The simultaneous occurrence of chronic heart failure (CHF) and chronic kidney disease
(CKD), known as the cardiorenal syndrome (CRS), is accompanied by high morbidity and
mortality [1,2]. Traditional risk factors only partly explain this high risk [3], suggesting that
additional pathophysiological mechanisms are involved. Several novel risk factors have been
implicated in the elevated cardiovascular risk in CKD. Prominent non-traditional risk factors
include red cell related measures such as anemia, iron status and red cell distribution width
(RDW) [4], and markers of mineral metabolism, especially fibroblast growth factor 23
(FGF23) [5]. Interestingly, recent studies suggest a mechanistic link between these two systems
[6–8].
FGF23 is a bone derived phosphaturic hormone that plays an important role in systemic
phosphate homeostasis and vitamin D metabolism. Several observational studies consistently
demonstrate independent associations between FGF23 and accelerated CKD progression [9],
left ventricular hypertrophy in dialysis and predialysis patients [10], and increased mortality
risk in CKD and hemodialysis patients and kidney transplant recipients [10–14]. Recently, it
was shown that iron status influences FGF23 catabolism in mice with autosomal dominant
hypophosphatemic rickets [6]. Similarly, in female patients with iron deficient anemia
markedly elevated C-terminal FGF23 (cFGF23) levels but not intact FGF23 (iFGF23) levels
were found [7]. Importantly, intravenous iron administration markedly reduced cFGF23 levels,
providing another clue that iron status influences FGF23 cleaving. The current hypothesis is
that, in healthy individuals, iron deficiency stimulates FGF23 production whereby osteocytes
couple increased production of FGF23 with increased cleavage to cFGF23 to maintain normal
circulating levels of iFGF23, which is the biologically intact hormone [15]. However, it is
unknown whether this finding holds for CKD, a disease characterized by disturbed iron metab-
olism, high FGF23 levels and increased risk for cardiovascular complications.
Red cell distribution width (RDW) is a measure of the variation of red blood cell volume,
defined as the standard deviation of erythrocyte size divided by the mean corpuscular volume.
RDW is a robust marker of adverse clinical outcomes in patients with chronic and acute heart
failure [16–19], coronary artery disease [20], acute kidney injury (AKI) [21] and even in the
community [22–24]. The pathophysiological mechanism responsible for the association
between RDW and adverse outcomes remains to be resolved, but could be related to disturbed
iron metabolism or inflammation [19,25]. Because both FGF23 and RDW are independently
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associated with poor outcome measures, and both seem to be affected by iron, it is interesting
to investigate whether a relation exists between FGF23 and RDW.
We hypothesized that a higher RDW is associated with more FGF23 cleavage, providing a
common pathway in which both markers lead to adverse outcomes. Therefore, we examined
the relationship between RDW and both intact and C-terminal FGF23 as well as the ratio
between the two, and the difference between cFGF23 and iFGF23, in a cohort of patients with
chronic kidney disease and chronic heart failure. Analyses were adjusted for markers of renal
function, iron status and inflammation.
Methods
Subjects
For the current study we performed a post hoc cross-sectional analysis of baseline data from
patients enrolled in the EPOCARES study (The Mechanisms of Erythropoetin Action in the
CardioRenal Syndrome, ClinicalTrials.gov NCT 00356733). The study design of the EPO-
CARES study has been published previously [26]. The study is being carried out in compliance
with the Helsinki Declaration, and the protocol has been approved at each participating center
by its internal review board. In short, the EPOCARES study is an open-label, prospective, ran-
domized trial in which patients with CHF, CKD (glomerular filtration rate 20–70 ml/min)
and mild anemia (hemoglobin 10.3–12.6 g/dL in men, and 10.3–11,9 g/dL in women) were
included to test the erythropoietic and non-erythropoietic responses to low-dose ESA treat-
ment. Patients with active systemic disease as a cause of CHF or CKD were excluded. Other
exclusion criteria were ESA therapy in the previous 6 months, bleeding, chronic inflammatory
disease or malignancy. In all patients, standard treatment was started, comprising oral iron
suppletion (ferrofumarate), calcium carbonate, aspirin when indicated and maximal tolerated
dosages of a β-blocker, an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin
receptor blocker, according to CHF guidelines. Included patients were randomized into 3
groups: 1 group received a fixed dose of 50 IU/kg per week EPO to increase hemoglobin level
to a maximum of 13.7 g/dL for men and 13.4 g/dL for women; another group was treated with
50 IU/kg per week EPO maintaining baseline hemoglobin levels for the first 6 months by phle-
botomy. The control group received standard care without EPO. This translational study was
designed primarily to discern hematopoietic from nonhematopoietic effects of erythropoietin
(EPO) in cardiorenal patients. All baseline data were derived prior to randomization and initia-
tion of EPO treatment.
The original study population of the EPOCARES study consisted of 62 patients. Five
patients withdrew their informed consent and one patient was excluded because of malignancy
diagnosed after inclusion. Baseline RDW data were missing for two patients and two outliers of
FGF23 were excluded, since these values exceeded the third quartile by a magnitude greater
than 1.5 (IQR).
Biochemical Analysis
Biochemical measurements were performed at baseline and blood samples were drawn
between 8 and 9 AM in supine position and stored immediately at -80°C until analysis.
Levels of Hb, hematocrit, MCV and RDW were measured using a Sysmex XE-2100 hema-
tology analyzer (Toa Medical, Kobe, Japan). Plasma interleukin-6 (IL-6) levels were measured
in duplo using a commercially available ELISA kit (R&D Systems, Minneapolis, USA).
As a marker of iron stores [27], ferritin was determined using a sandwich immunoassay on
an Acces 2 immunoanalyzer within a Dx automated system from Beckman Coulter (Brea, CA).
Function iron availability was determined by measuring transferrin saturation (TSAT) and was
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calculated from serum iron and transferrin estimates obtained with standard methods on a
Beckman Coulter Dx. Renal function was estimated by means of MDRD. Reference values of
all parameters are shown in Table 1.
FGF23 was analyzed with two validated assays [28]. The iFGF23 was determined in serum
using a sandwich ELISA, (Kainos Laboratories, Tokio, Japan), the intra- and interassay CV’s
are<10% and<14%, respectively. The cFGF23 was assessed in EDTA-plasma using a sand-
wich enzyme-linked immunosorbent assay (ELISA) (Immutopics, San Clemente, CA, USA).
The intra- and interassay CV’s are<5% and<16%, respectively. The former assay detects
only the full-length FGF23, while the latter assay additionally measures the c-terminal frag-
ments of truncated FGF23. In order to estimate the amount of intact FGF23 in relation to
the total amount of FGF23 (i.e. intact FGF23 + C-terminal FGF23 as measured by the C-
terminal assay), we calculated the iFGF23/cFGF23 ratio. We also estimated the absolute
amount of C-terminal fragments by calculating the difference between total FGF23 and
iFGF23.
Table 1. Main clinical and biochemical characteristics of patients from the EPOCARES study at baseline.
Characteristics* All patients n = 52 Reference values
Age (yrs) 73 [69–80]
Male sex, n (%) 33 (63.5%)
Smoking (%) 11.5%
BMI kg/m² 25.9 [23.7–29.9]
Diabetes Mellitus 36.5%
Hypertension 78.8%
Hemoglobin (g/dL) 11.8 ± 0.9 12.5–16.1 g/dL (f)
13.7–17.0 g/dL (m)
Hematocrit (L/L) 0.35 ± 0.03 0.36–0.48 L/L (f)
0.40–0.52 L/L (m)
MCV (/μm³) 90 ± 4 80–102
RDW (%) 14.1 ± 1.2 10.4–13.0%
MDRD (ml/min/1.73m²) 35 ± 14 > 60 ml/min/1.73m²
NT-proBNP (pg/mL) 1387 [688–2370] <738 pg/ml
Ferritin (ng/mL) 129 [75–179] 10–200 ug/l
Iron (μmol/L) 10 [8.8–14] 9–30 umol/l
TSAT (%) 20 [16.3–25] < 45%
CRP (mg/L) 5 [2–11.3] 0–10 mg/l
IL-6 (pg/mL) 3.27 [1.9–5] < 10 pg/mL
iFGF23 107.3 [65.1–162.2] 20–50 pg/ml
cFGF23 197.5 [110–408.5] < 125 RU/ml
iFGF23/cFGF23 0.803 [0.37–0.86]
PTH 10.4 [6.7–15] 1.5–7 pmol/l
Phosphate 1.15 [1–1.2] 0.80–1.45 mmol/l
BMI = body mass index, MCV = mean corpuscular volume, RDW = red cell distribution width, MDRD = estimated glomerular ﬁltration rate by modiﬁed diet
in renal disease formula, NT-proBNP = N-terminal pro-brain natriuretic peptide, TSAT = transferrin saturation, CRP = C-reactive protein, IL-6 = interleukin
6, iFGF23 = intact ﬁbroblast growth factor 23, cFGF23 = C-terminal ﬁbroblast growth factor 23, PTH = parathyreoid hormone.
*values in mean ± standard deviation or median [interquartile range]
doi:10.1371/journal.pone.0128994.t001
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Statistical Analysis
Continuous variables at baseline were summarized as the mean ± standard deviation (SD) if
normally distributed or otherwise as medians with interquartile range (IQR). Skewed variables
were transformed to natural logarithms after which normality was checked again. After check-
ing model assumptions, univariate linear regression analyses were used to test the relationship
between iFGF23, cFGF23 and the difference between cFGF23 and iFGF23 (cFGF23-iFGF23)
with RDW. The ratio iFGF23/cFGF23 was divided in tertiles because of violation of linearity
and we used two dummies to estimate the regression coefficient between ratio iFGF23/cFGF23
and RDW. FGF23 was used as independent variable and RDW as dependent variable. To test
the relationship between FGF23 and TSAT, univariate regression analysis was performed with
TSAT as independent and FGF23 as dependent variable. Subsequently, four multivariable lin-
ear regression models were used to adjust for confounding of the primary analysis (RDW and
cFGF23). A 10% change of the regression coefficient was considered to indicate relevant con-
founding. Model 1 adjusted for potential confounders of the relationship between cFGF23 and
RDW derived from the literature [29–31]: eGFR, PTH, phosphate, BMI and smoking. Model 2
adjusted for variables used in model 1 and in addition markers of iron metabolism (TSAT and
ferritin). Model 3 adjusted for variables used in model 1 and in addition markers of inflamma-
tion (IL-6 and CRP). In the final model 4, a combination of previous models was used to adjust
for all possible confounders. Age and sex were ruled out to be effect modifiers. For statistical
analysis, the SPSS software package version 20 was used (SPSS, IBM, Chicago, IL, USA).
Results
Population Characteristics
Demographics, baseline laboratory data and clinical characteristics of the 52 patients enrolled
into this study are reported in Table 1.
Median age was 73 years (IQR 69–80) and 63.5% were male (Table 1). Of the population
included in this study 11.5% were smokers and on average BMI was elevated (median 25.9,
IQR 23.7–29.9). The mean RDW value was 14.1% ± 1.2, with a reference range of 10.4–13.0%
and the mean eGFR 35 ± 14 ml/min/1.73m2. Both iFGF23 (median 107.3 pg/ml, IQR 65.1–
162.2) and cFGF23 levels (median 197.5 RU/ml, IQR 110–408.5) were increased. CRP levels
were only slightly elevated, showing that the study involved chronic stable patients in a rela-
tively low-inflammatory state. Ferritin levels and TSAT were low-normal.
Relation between FGF23 and TSAT
Univariate linear regression was performed to estimate the relation between FGF23 and TSAT.
A statistically significant association was found between TSAT and cFGF23 (β = -12.35,
P = 0.03), but not between TSAT and iFGF23 (β = -1.86, P = 0.31).
Relation between FGF23 and RDW
Univariate linear regression showed a statistically significant relationship between cFGF23 and
RDW (β = 1.63 x 10−3, P<0.001) in our population (Fig 1A), but not between iFGF23 and
RDW (β = -1.38 x 10−3, P = 0.34, Fig 1B). The difference between cFGF23 and iFGF23
(cFGF23-iFGF23, representing the amount of c-terminal FGF23 fragments) was positively cor-
related with RDW (β = 1.74x10-3, P< 0.001, Fig 1C). In order to comply with the conditions
for linear regression, we divided the iFGF23/cFGF23 ratio (representing the fraction of intact,
biologically active FGF23) into tertiles. Both the second and the third tertile of the iFGF23/
cFGF23 ratio were associated with RDW (β = -0.947, P = 0.014 and β = -1.253 and P = 0.002).
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This might be explained by reduced iron availability, as iron availability is a determinant of
both RDW as well as the iFGF23/cFGF23 ratio due to increased cleavage of iFGF23 into C-ter-
minal fragments in conditions of reduced iron availability.
To further analyze the relation of cFGF23 with RDW, we constructed several models to
adjust for potential confounders (Table 2). Adjustment for eGFR, PTH, phosphate, BMI and
smoking (model 1) did not modify the regression coefficient significantly between cFGF23 and
RDW (β = 1.5 x 10−3, P = 0.001). Further adjustment for indicators of iron deficiency, ferritin
and TSAT (model 2), marginally attenuated the association (β = 1.34 x 10−3, P = 0.003). Model
Fig 1. The relationship between baseline cFGF23 and RDW (A), baseline iFGF23 and RDW (B) and
between cFGF23-iFGF23 and RDW (C).
doi:10.1371/journal.pone.0128994.g001
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3, correcting for variables used in model 1 and for CRP and IL-6 as markers of inflammation,
further attenuated the strength of the cFGF23-RDW association (β = 1.08x10-3, P = 0.023).
After adjusting for all mentioned variables (model 4), the association between cFGF23 and
RDW remained statistically significant (β = 0.969x10-3, P = 0.047).
In a sensitivity analysis, further adjusted for hypertension, diabetes mellitus, hemoglobin
level and 25-hydroxyvitamin D did not influence this relation (data not shown).
Discussion
The main finding of this study is the strong and robust association between cFGF23 levels and
RDW in patients with CKD and CHF, which persisted after adjustment of several potential
confounders. Interestingly, in contrast with the consistent association between cFGF23 and
RDW, no association between iFGF23 and RDWwas observed. Our results are in line with pre-
vious observations connecting red cell properties with phosphate homeostasis [6,7]. As both
red cell properties and calcium/phosphate homeostasis are important prognostic factors in
CKD, detailed knowledge about their interaction could provide novel insights into the etiology
of combined CHF and CKD and the subsequent deteriorated prognosis.
Currently, the underlying pathophysiological mechanisms linking FGF23 and RDW with
outcome are unknown. Our data suggest an association between cFGF23 and RDW, raising the
question whether there is an unknown factor that directly affects the risk of adverse outcome
in combined CHF and CKD and whether this also affects both RDW and FGF23. Therefore,
co-aggregation of changes in FGF23 and RDW caused by an established factor associated with
renal function (i.e. potential confounding) should be ruled out. We adjusted for several poten-
tial confounders, known to influence FGF23 concentrations, based on the literature (eGFR,
PTH, phosphate, smoking, and BMI) [29–31]: this did not substantially mitigate the strength
of the association between RDW and FGF23.
Recent data demonstrated that iron deficiency can increase cFGF23, possibly as a result of
increased FGF23 cleaving [6,7]. Wolf et al. demonstrated that iron deficiency stimulates FGF23
transcription whereby increased levels of iFGF23 are cleaved intracellularly into cFGF23 in
healthy humans as such limiting its physiological effects on phosphate homeostasis. Therefore,
Table 2. Multivariable linear regression for association between cFGF23 and RDW after adjustment
for confounders.
Y = RDW Regression coefﬁcient p-value
Crude analysis
cFGF23 RU/ml 1.63 x 10−3 <0.001
Adjusted analysis 1*
cFGF23 RU/ml 1.50 x 10−3 0.01
Adjusted analysis 2*
cFGF23 RU/ml 1.34 x 10−3 0.003
Adjusted analysis 3*
cFGF23 RU/ml 1.08 x 10−3 0.023
Adjusted analysis 4*
cFGF23 RU/ml 0.97 x 10−3 0.047
1. Adjusted for eGFR, PTH, Phosphate, BMI and smoking
2. Adjusted for eGFR, PTH, phosphate, BMI, smoking, ferritin and TSAT
3. Adjusted for eGFR, PTH, phosphate, BMI, smoking, IL-6 and CRP
4. Adjusted for eGFR, PTH, phosphate, BMI, smoking, ferritin, TSAT, IL-6 and CRP
doi:10.1371/journal.pone.0128994.t002
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iron metabolism may be a link between FGF23 and RDW in our patients with combined
chronic heart and renal failure. Although we found a significant association between cFGF23
and TSAT, the association between cFGF23 and RDW was only marginally attenuated by
TSAT and ferritin. This suggests that additional mechanisms could be involved. Of note, the
study design of the EPOCARES study included oral iron supplementation in all groups.
In addition to iron metabolism, inflammation stands out as a potential mechanism explain-
ing the association between FGF23 and RDW. Higher levels of FGF23 are independently
associated with inflammation in patients with CKD [32] and high RDW values have been asso-
ciated with plasma markers of inflammation in a large cohort of unselected adult outpatients
[33] and in patients with heart failure [17]. Indeed, our subsequent analysis showed that the
strength of the association between cFGF23 and RDW was attenuated, but not abolished, after
adjusting for CRP and IL-6. Taken together, the association between cFGF23 and RDWmay
be partly explained by iron metabolism as well as by inflammation but remains statistically sig-
nificant after adjustment for these factors, indicating that additional unknown factors may link
cFGF23 and RDW.
Alternatively, cFGF23 may directly influence RDW. Although there is some debate, several
studies demonstrate FGF23 effects on the vessel wall [34–36]. Endothelial responses to a high
FGF23 level could induce suicidal red blood cell death (eryptosis) with a reactive rise in RDW
[16,25]. As has been shown in animal model, the presence of c-terminal FGF23 fragments may
modulate FGF23 mediated effects and as such the role of endothelial cells on erythrocyte turn-
over can be influenced [37].
Additional mechanistic studies linking iron metabolism, FGF23 and red cell fate are relevant
in CKD given the high risks of cardiovascular disease and death in these patients. Future
research in which FGF23 levels are manipulated in order to influence RDW could possibly lead
to a potential therapeutic intervention and improve the cardiovascular outcome in CKD
patients. Conversely, it may be of importance to investigate the effect of influencing RDW (via
iron manipulation) on FGF23 production and cleavage in osteocytes. If indeed cFGF23 is toxic
to vessels, targets to interfere in the FGF23 secretion and catabolism could be helpful in pre-
venting cardiovascular diseases.
Limitations of the study as a result of sample size need to be acknowledged. The size of our
cohort which was based on the EPOCARES study is relatively small; yet the observed associa-
tion between cFGF23 and RDW was robust in multivariate analyses. Furthermore, this study,
performed among elderly people with CKD and CHF, may not be generalized to the entire
CKD population. Finally, no cause-effect relationship can be established from this study due to
its cross-sectional nature. The assumption that c-terminal FGF23 has its effect on the vascular
wall is purely speculative, so we consider this a hypothesis-generating study that serves to fuel
future prospective studies.
Strong points of our study include the fact that we measured both C-terminal and intact
FGF23, which allowed us to obtain specific information on FGF23 cleaving, and the fact that
we adjusted our analyses for markers of iron status and inflammation. However, this also yields
a limitation, as the comparison of the results of the two assays measuring cFGF23 and iFGF23
is difficult due to the use of different units. Since the proportion of FGF23 that is cleaved is
unknown, cFGF23 can only be reported as unit/volume. The two assays may detect different
FGF23 epitopes and therefore in biological systems the affinity for these respective epitopes
may differ and explain limited linearity between these two ELISAs. This may apply in our EPO-
CARES subjects as well. However, our group has published results comparing the two assays in
a range of concentrations and demonstrated a reasonable linearity of both assays [28]. We
decided to use iFGF23:cFGF23 ratio as a measure for the amount of cleaved FGF23 present, in
accordance with recommendations by others [15].
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In conclusion, our study demonstrates an association between cFGF23 and RDW but not
iFGF23, suggesting that RDW is linked with FGF23 cleaving. Although iron deficiency and
inflammation are known determinants of RDW as well as FGF23 metabolism, these factors
only partly explained the association between RDW and FGF23. Further research is warranted
to address additional mechanisms driving the association between FGF23 and red cell metabo-
lism, and particularly RDW, in patients with CKD and CHF.
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